ArticleIranian Red Crescent medical journal2016
Evaluation of Iron Oxide Nanoparticles Toxicity on Liver Cells of BALB/c Rats.
Article in Iranian Red Crescent medical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Magnetic Hyperthermia with Iron Oxide Nanoparticles: From Toxicity Challenges to Cancer Applications.Nanomaterials (Basel, Switzerland) · 2025Review
- Liver-targeting iron oxide nanoparticles and their complexes with plant extracts for biocompatibility.Beilstein journal of nanotechnology · 2024Article
- LGR5 as a Therapeutic Target of Antibody-Functionalized Biomimetic Magnetoliposomes for Colon Cancer Therapy.International journal of nanomedicine · 2024Article
- Article
- Metal-Based Nanoparticles and Their Relevant Consequences on Cytotoxicity Cascade and Induced Oxidative Stress.Antioxidants (Basel, Switzerland) · 2023Review
- Ameliorative Effect of Pomegranate Peel Extract (PPE) on Hepatotoxicity Prompted by Iron Oxide Nanoparticles (FeNanomaterials (Basel, Switzerland) · 2022Article
- Humic Acid-Coated FePolymers · 2022Article
- Administration Routes as Modulators of the Intrahepatic Distribution and Anti-Anemic Activity of Salicylic Acid/Fe3O4 Nanoparticles.Biomedicines · 2022Article
- Impacts of dietary supplementation with nano-iron and methionine on growth, blood chemistry, liver biomarkers, and tissue histology of heat-stressed broiler chickens.Tropical animal health and production · 2022Article
- Understanding Nanomaterial-Liver Interactions to Facilitate the Development of Safer Nanoapplications.Advanced materials (Deerfield Beach, Fla.) · 2022Review
- Article
- Mechanical behaviors and probabilistic multiphase network model of polyvinyl alcohol hydrogel after being immersed in sodium hydroxide solution.RSC advances · 2021Article
- Systemically delivered antibody-labeled magnetic iron oxide nanoparticles are less toxic than plain nanoparticles when activated by alternating magnetic fields.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2020Article
- Organ Metallome Processed with Chemometric Methods Enable the Determination of Elements that May Serve as Markers of Exposure to Iron Oxide Nanoparticles in Male Rats.Biological trace element research · 2020Article
- State-of-Art Bio-Assay Systems and Electrochemical Approaches for Nanotoxicity Assessment.Frontiers in bioengineering and biotechnology · 2020Review
- Immunotoxicity Considerations for Next Generation Cancer Nanomedicines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Review
- Multifunctional Superparamagnetic Stiff Nanoreservoirs for Blood Brain Barrier Applications.Nanomaterials (Basel, Switzerland) · 2019Article
- Magnetic Hyperthermia and Radiation Therapy: Radiobiological Principles and Current PracticeNanomaterials (Basel, Switzerland) · 2018Review
- Dose Dependencies and Biocompatibility of Renal Clearable Gold Nanoparticles: From Mice to Non-human Primates.Angewandte Chemie (International ed. in English) · 2018Article
- Liver Histopathological Changes Related to Intraperitoneal Administration of Salicylic Acid/Fe3O4 Nanoparticles to C57BL/6 Mice.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBecause of their unique magnetic properties, Fe3O4 nanoparticles (Fe3O4-NPs) have extensive applications in various biomedical aspects. Investigation of the possible adverse aspects of these particles has lagged far behind their fast growing application.
objectivesThe current study aimed to evaluate the toxicity of Fe3O4-NPs in the liver of mice. MATERIALS AND
methodsIn the present clinical trial, 90 BALB/c mice were randomly divided in 15 groups. Five control groups were fed by usual water and food. Five placebo groups were gavaged with physiological serum in doses of 25, 50, 75, 150, and 300 micrograms per gram of body weight (μg/gr). Five experimental groups were gavaged with Fe3O4-NPs, in doses of 25, 50, 75, 150, and 300 μg/gr. This pattern was repeated every other day, for 3 days. Then, the levels of liver enzymes [alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)] were compared between these groups. The histological alterations of livers were examined, as well. For statistical analysis, Kruskal-Wallis and Mann-Whitney, with type I Bonferroni correction, as post-hoc, have been used.
resultsThe administration of 150 and 300 μg/gr doses of Fe3O4-NPs were associated with significant elevation in liver enzymes, compared to controls (P < 0.0001). Furthermore, the histopathological effects were observed in the liver tissue of these groups. However, in groups treated with lower doses of Fe3O4-NPs, no significant adverse effect was observed.
conclusionsBased on our results, the administration of Fe3O4-NPs causes dose dependent adverse effects on liver.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.